Trenimon

Trenimon is a compound with anti-cancer effects. Trenimon shows mutagenic actions in many species by inducing point and chromosomal mutations, sister-chromatid exchanges, recombination phenomena and phage induction. Trenimon can be used for the research of cancer^[1][2][3][4]. In Vitro:Trenimon (0.17 mM) penetrates readily into mouse lymphoma cells in vitro^[1].
Trenimon (0.17 nM; 5 min-16 h) time-denpendently reduces the priming activity of DNA^[2].
Trenimon (1 nM-10 μM; 10-20 min) leds HeLa cells death after 2 weeks with a dose of 10 μM and dose-dependently suppresses mitosis in cells^[3]. In Vivo:Trenimon (0.25 mg/kg; i.p. once) rapidly depresseas of the cellular elements of the peripheral blood (granulocytes, lymphocytes, reticulocytes, platelets and erythrocytes), and reduces the cell number of bone marrow^[4].
Trenimon (0.03 mg/kg; i.v. once per week for 52 weeks) shows an cancerogenic effect in vivo^[4].